Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Average (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Equity Average for 10 consecutive years, with $37.1 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 174.51% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 174.51% year-over-year, with the annual reading at -$8.3 million for FY2025, 79.22% up from the prior year.
  • Equity Average for Q4 2025 was $37.1 million at Akebia Therapeutics, up from $35.4 million in the prior quarter.
  • The five-year high for Equity Average was $229.1 million in Q1 2021, with the low at -$49.8 million in Q4 2024.
  • Average Equity Average over 5 years is $32.6 million, with a median of $16.8 million recorded in 2022.
  • The sharpest move saw Equity Average tumbled 618.97% in 2023, then surged 188.19% in 2025.
  • Over 5 years, Equity Average stood at $105.6 million in 2021, then tumbled by 93.61% to $6.7 million in 2022, then crashed by 618.97% to -$35.0 million in 2023, then plummeted by 42.26% to -$49.8 million in 2024, then soared by 174.51% to $37.1 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $37.1 million, $35.4 million, and $26.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.